Teva UK Limited launches generic Letrozole tablets

We are pleased to announce the launch of generic letrozole film-coated tablets.

Letrozole is a generic version of Femara® (letrozole) from Novartis Pharmaceuticals UK Ltd and is indicated in the following therapeutic indications:

• Adjuvant treatment of post-menopausal women with hormone receptor-positive early breast cancer
• Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years
• First-line treatment in post-menopausal women with hormone-dependent advanced breast cancer
• Advanced breast cancer in women with natural or artificially-induced post-menopausal status after relapse or disease progression, who have previously been treated with anti-oestrogens.

Letrozole from Teva UK Limited is available immediately as 2.5 mg film-coated tablets in packs of 14 and 28, in the award-winning Teva 360 packaging, which has been designed to aid patient safety.

The Teva retail price for the product is £7.49 for the packs of 14 film-coated tablets and £12.73 for the packs of 28.

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.